Novartis AG (NVS)

86.28
0.25 0.29
NYSE : Health Technology
Prev Close 86.53
Open 86.29
Day Low/High 85.85 / 86.63
52 Wk Low/High 74.97 / 96.31
Volume 1.42M
Avg Volume 1.89M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 218.34B
EPS 5.50
P/E Ratio 16.08
Div & Yield 1.84 (2.14%)
Profit From the Longer Life Spans, Part 1

Profit From the Longer Life Spans, Part 1

Americans are living much longer these days -- and there are a number of ways to invest.

Riding the Coattails of Mega-Caps

A selection based on James P. O'Shaughnessy's strategy.

Budweiser and Gerber Among Larger U.S. Brands Overseas

Budweiser and Gerber Among Larger U.S. Brands Overseas

Some of the most well-known American brands aren't actually so American, after all.

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

What to Watch Monday, May 5: Earnings From Drug Giant Pfizer

Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.

Day Ahead: Awash in Earnings

Futures point higher; blockbuster drug deal boosts European markets.

Day Ahead: Quarter Final

Update: Futures positive as quarter closes; J&J sells ortho unit.

Array CEO: Partnerships Smart While Cancer Drug Develops

Array CEO: Partnerships Smart While Cancer Drug Develops

Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.

Rules of the Game: In International Waters

When investing beyond your own shores, choose value over growth.

Looking Across the Pond

Some European names look ripe for investment right now.

Early-Morning Market Look

Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...

Takeover Bait for Profitable 2013 Fishing

Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern. 

A Prescription for Election Fever

Now is the time to pop the pharmaceutical pill and buy.

UBS Posts Worse-than-Expected Q2 Profit: Hot Trends

UBS Posts Worse-than-Expected Q2 Profit: Hot Trends

A look at the day's most searched trends on the Web, including UBS after the Swiss bank posted a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.

Two Stocks Near 9-Month Consolidation

Two Stocks Near 9-Month Consolidation

IRM has been trading in a declining triangle pattern since July. Technical indications of NVS are also positive.

Amgen Founding CEO George B. Rathmann Dies: Hot Trends

Amgen Founding CEO George B. Rathmann Dies: Hot Trends

A look at the day's most searched trends on the Web, including Amgen after the passing of its founding CEO.

The Anatomy of a Head-and-Shoulders Bottom

The Anatomy of a Head-and-Shoulders Bottom

Plenty of stocks are exhibiting these formations -- here's how to tell where they'll go from here.

The Day Ahead: Selling Pressure Mounts

Indicators pointed to a not-so-super Tuesday, as international growth concerns weighed on U.S futures.

The Day Ahead: JPMorgan Earnings in the Mix

Futures point to a mixed open ahead of several economic reports and slumping earnings from JPMorgan.

Mylan, Teva Break Through

Mylan, Teva Break Through

These two pharmaceuticals are standouts as the sector outperforms today.

Spotting the Best Swiss Stocks

Despite worries of a rising franc, there are Swiss companies that check all the boxes for your portfolio.

The Day Ahead: Debt Deal Disappoints

A relief rally failed to materialize, and Wall Street futures are pointing to a lower open.